ELOX vs. ONVO, TCBP, CHRO, TTNP, FRTX, BCDA, SRNE, CELZ, ALBT, and PALI
Should you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Organovo (ONVO), TC Biopharm (TCBP), Chromocell Therapeutics (CHRO), Titan Pharmaceuticals (TTNP), Fresh Tracks Therapeutics (FRTX), BioCardia (BCDA), Sorrento Therapeutics (SRNE), Creative Medical Technology (CELZ), Avalon GloboCare (ALBT), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
Eloxx Pharmaceuticals (NASDAQ:ELOX) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.
Organovo received 183 more outperform votes than Eloxx Pharmaceuticals when rated by MarketBeat users. Likewise, 49.62% of users gave Organovo an outperform vote while only 43.33% of users gave Eloxx Pharmaceuticals an outperform vote.
In the previous week, Organovo had 2 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 2 mentions for Organovo and 0 mentions for Eloxx Pharmaceuticals. Organovo's average media sentiment score of 1.44 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Organovo is being referred to more favorably in the news media.
Eloxx Pharmaceuticals has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Eloxx Pharmaceuticals' return on equity of 0.00% beat Organovo's return on equity.
Organovo has higher revenue and earnings than Eloxx Pharmaceuticals. Organovo is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Organovo beats Eloxx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Eloxx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eloxx Pharmaceuticals Competitors List
Related Companies and Tools
